You are here:
Extension of indication to include paediatric patients (3 months to 18 years of age) for hepatic and cardiac transplants and to extend the indication for renal transplants for paediatric patients starting from 3 months
No estimate possible yet
Registration application pending
Mycofenolaatmofetil
Oncology
Indication extension
Roche
Centralised (EMA)
Normal trajectory
June 2023
September 2024
There is currently nothing known about the expected patient volume.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines